We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Agree. I think the recent movements are inevitable given the big-name tie-up, but it'll be interesting to see how they're able to capitalise on it to boost sales. I have some doubts but a hold nonetheless
Write up for interest after catching up with the CEO last week.
https://martinflitton1.wixsite.com/privatepunter
Diaceutics PLC - Belfast-based provider of diagnostic commercialisation services to pharmaceutical and biotechnology companies - Announces strategic alliance with KPMG LLC, which provides tax, audit and advisory services and commercialisation solutions for life sciences and healthcare companies. Diaceutics says the partnership will facilitate joint marketing of commercialisation solutions to life science customers for commercialisation of precision medicines.
Diaceutics Chief Executive Officer Ryan Keeling says: "We have worked alongside KPMG leaders for many years with a strong admiration for their work in the precision medicine space. This alliance formally recognises our common goals and ambitions to collectively shape the future of precision medicine...[and] will make it easier for the world's largest and most innovative pharmaceutical and biotech organisations to get access to the best expertise and the best data available."
Nice buys coming in
Yep, buys coming in quickly now...lunchtime over and they've seen the RNS
...KMPG Strategic alliance news getting around now....wait for the press coverage
Buys coming in strong
Moving up now £££
EXPECT SOME PRESS COVERAGE COMING IN SOON AND WE WILL SEE ALOT MORE PEOPLE AS NEWS HAS JUST COME OUT
NEW JUST OUT
People haven't seen RNS yet, or they'd be jumping on board. It is lunchtime!
Wow great RNS OUT TODAY
1 MM already sitting on 1.10 😎
NEWS
Amazing news
RNS out ... Diaceutics PLC - Strategic alliance with KPMG
Downtrend line drawn from 23/2/23 through peak of 25/9/23, is in vicinity of current sp. Since there has already been a significant rise from the preceding, lower trough, a price breakout upward, seems unlikely. Having said that, the price formations,although still in a sideways trend, have been forming higher bottoms and lower tops, which is indicative of a tightening in the overall price dynamic. I feel that DXRX, may require some more sp, tightening, involving perhaps another higher bottom, so a drop in price from the current level seems likely, but an equity to keep on a watchlist, for investment.
The trouble with great oak trees is, as you say, over time. And they've had quite a bit of time. I've not yet seen the shoot from the acorn, never mind the sapling (to extend your metaphor) but the market offers exciting prospects so let's see!
The stock has seen net accumulation over the last 7 weeks with some significant volume spikes indicating ( IMHO), the inflow of some well- informed investors. I am content to initiate an initial position below the price at which the CFO purchased >£22k of shares in 23rd June. I'll accumulate up to a £10k position with a trailing stop loss. Enabling the development of Precision Medicine is an important theme linked to the increased personalisation of oncology treatments. I have an Oncology background and work in the NHS , so I can claim to have some insights in this niche area. Diaceutics is " under the radar" of most investors. Let's hope that the old adage of : " from small acorns grow great oak trees" applies here over time!
Lots of big buys at 85.5p today all shown as unknowns.
Further good news from this underrated company. With two pieces of good news this year, I wouldn't be surprised if the company achieves £25m full year turnover with a EBIT of £2m+. Could dividends be on the cards soon?
Nice news this morning following the VG results in April. A justified sea of blue this morning for this overlooked gem. Long term hold me thinks.
Diaceutics CFO, Nick Roberts & CIO Ryan Keeling present full year results for the period ended 31 December 2022, which shows a strong trading performance with continued momentum driving strategic investment into 2023.
Watch the video here: https://www.piworld.co.uk/company-videos/diaceutics-dxrx-full-year-2022-results-presentation-april-2023/
Listen to the podcast here: https://piworld.podbean.com/e/diaceutics-dxrx-full-year-2022-results-presentation-april-2023/
Very good set of results yesterday. Well done to the team. And great prospects. Profitable with a strong balance sheet. What's not to like?